Negotiators convened in Geneva this week for the Ninth Session of the Biological and Toxin Weapons Convention Working Group, facing mounting pressure to advance a decade-old mandate to strengthen the 1972 treaty before the 2027 Review Conference. With only two days remaining in the current August session and a final four-day meeting scheduled for December, the Working Group must finalize recommendations across seven issue areas: international cooperation, scientific and technological developments, confidence-building measures, verification, national implementation, response preparedness, and institutional arrangements.
By the second day of negotiations, as reported by the BioWeapons Prevention Project (BWPP), 90.6% of draft report text had been agreed upon, yet fundamental disagreements over verification frameworks, transfer controls, and donor eligibility for a proposed international cooperation fund threaten completion. The Chair, Ambassador Frederico S Duque Estrada Meyer of Brazil, set aside three contentious topics: economic sanctions as a compliance tool, decision-making procedures for new oversight bodies, and which powers the annual Meeting of States Parties should hold. Despite this move to facilitate progress, tensions remain high.
The Working Group is tasked with establishing two mechanisms: one to review scientific and technological developments relevant to the Convention, and another to facilitate international cooperation and assistance under Article X. Both mechanisms require consensus approval, meaning every state party must agree on final language. Russia and Iran have raised formal objections to various provisions, complicating efforts to reach consensus.
A dispute over trust fund financing has emerged as particularly contentious. Most delegations favor allowing non-state actors such as the European Union to contribute money, which would expand available funding. The USA objected to finalizing language that would permit such contributions, keeping the issue unresolved. Other delegations expressed concern that the USA appears to have shifted its position on this issue without clearly explaining its reasoning.
The Working Group Chair highlighted a central driver of urgency: the rapid convergence of artificial intelligence and biology, which he noted is “creating new security challenges while opening important opportunities for scientific and medical progress.” He warned that “a gap may emerge between these rapidly advancing capabilities and our collective ability to understand their governance and prevent their misuse.”
Negotiations resume through August 21, with a final Working Group session in December. The 2027 Review Conference will decide which recommendations take immediate effect and which await implementation at the 2032 Review Conference.
This article is based on reporting from the BioWeapons Prevention Project (BWPP), which provides detailed coverage of all BWC meetings. For ongoing analysis of WG9 negotiations and the 2027 Review Conference process, visit the BWPP website.
This article was researched and sourced by Global Biodefense editors and reported with Claude AI assistance for drafting and editing.